Development
Bristol-Myers Squibb Company
BMY
$48.44
$0.631.32%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 8.03B | 8.29B | 7.96B | 7.31B | 6.33B |
| Total Depreciation and Amortization | 9.77B | 9.80B | 9.99B | 10.08B | 10.28B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.02B | -1.94B | -2.75B | -1.94B | -1.31B |
| Change in Net Operating Assets | -1.91B | -3.23B | -3.35B | -3.23B | -2.23B |
| Cash from Operations | 13.86B | 12.91B | 11.85B | 12.22B | 13.07B |
| Capital Expenditure | -1.21B | -1.23B | -1.13B | -1.14B | -1.12B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1.17B | -704.00M | -3.64B | -3.92B | -4.29B |
| Divestitures | 909.00M | 1.38B | 1.35B | 1.35B | 1.31B |
| Other Investing Activities | -826.00M | 814.00M | 2.01B | 2.35B | 3.04B |
| Cash from Investing | -2.30B | 264.00M | -1.41B | -1.37B | -1.06B |
| Total Debt Issued | 4.46B | 369.00M | 307.00M | 280.00M | 6.12B |
| Total Debt Repaid | -4.00B | -1.88B | -4.66B | -7.30B | -11.43B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -5.16B | -7.57B | -4.16B | -3.25B | -8.00B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.74B | -4.73B | -4.69B | -4.65B | -4.63B |
| Other Financing Activities | 27.00M | 181.00M | 193.00M | 559.00M | 984.00M |
| Cash from Financing | -9.42B | -13.63B | -13.01B | -14.36B | -16.96B |
| Foreign Exchange rate Adjustments | 45.00M | 62.00M | 34.00M | -29.00M | -33.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.19B | -389.00M | -2.54B | -3.53B | -4.99B |